Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Christopher Nicholas, PhD
News
Psychedelics Show Potential to Improve SUD Treatment Outcomes
10/31/2023
Tom Valentino, Digital Managing Editor
With drug overdose deaths continuing to climb, Sana Symposium presenter Christopher Nicholas, PhD, said studies suggest that incorporating the use of psychedelics into treatment modalities could improve outcomes.
With drug overdose deaths continuing to climb, Sana Symposium presenter Christopher Nicholas, PhD, said studies suggest that incorporating the use of psychedelics into treatment modalities could improve outcomes.
With drug overdose deaths...
10/31/2023
Psych Congress Network
Andrew Penn, RN, PMHNP, and Charles Raison, MD
News
Studies Illustrate Potential of MDMA-, Psilocybin-Assisted Therapies
10/30/2023
Tom Valentino, Digital Managing Editor
Andrew Penn, RN, PMHNP, and Charles Raison, MD, shared findings from late-stage trials for MDMA-assisted therapy to treat post-traumatic stress disorder and the use of psilocybin for treatment-resistant depression and major depressive...
Andrew Penn, RN, PMHNP, and Charles Raison, MD, shared findings from late-stage trials for MDMA-assisted therapy to treat post-traumatic stress disorder and the use of psilocybin for treatment-resistant depression and major depressive...
Andrew Penn, RN, PMHNP, and...
10/30/2023
Psych Congress Network
Single-Dose Psilocybin Linked With Rapid, Sustained Gains in Patients With MDD
News
Single-Dose Psilocybin Linked With Rapid, Sustained Gains in Patients With MDD
09/18/2023
Jolynn Tumolo
A single 25-mg dose of psilocybin plus psychological support was associated with an improvement in depressive symptoms compared with active placebo in adults with MDD, according to a study published in JAMA.
A single 25-mg dose of psilocybin plus psychological support was associated with an improvement in depressive symptoms compared with active placebo in adults with MDD, according to a study published in JAMA.
A single 25-mg dose of...
09/18/2023
Psych Congress Network
Rick Doblin, PhD.
Q&As
Anticipating Access Obstacles for Psychedelic-Assisted Therapies
10/17/2022
Rick Doblin, PhD, explains what clinicians should be thinking about in regards to accessibility for psychedelic therapies, when access should be limited, and common misconceptions that need to be cleared up.
Rick Doblin, PhD, explains what clinicians should be thinking about in regards to accessibility for psychedelic therapies, when access should be limited, and common misconceptions that need to be cleared up.
Rick Doblin, PhD, explains what...
10/17/2022
Psych Congress Network
News
Experts Share 2 Top Tools for Peer Support in Psychedelics
10/14/2022
Evi Arthur
Techniques to make this therapeutic tool more effective and help build connection with patients.
Techniques to make this therapeutic tool more effective and help build connection with patients.
Techniques to make this...
10/14/2022
Psych Congress Network
Zach Skiles
A Patient's Lived Experience With Psychedelic-Assisted Therapy: Sana Symposium Keynote Preview
10/13/2022
At the 2nd annual Sana Symposium, Zach Skiles, PsyD will share his lived experience with psychedelic-assisted therapy.
At the 2nd annual Sana Symposium, Zach Skiles, PsyD will share his lived experience with psychedelic-assisted therapy.
At the 2nd annual Sana...
10/13/2022
Psychiatry & Behavioral Health
Dr Rakesh Jain
Videos
Parsing Peer Review Literature on Psychedelics With Dr Rakesh Jain
10/13/2022
Rakesh Jain, MD, MPH, offers practical strategies to clinicians seeking to stay up to date in the field of psychedelic medicine.
Rakesh Jain, MD, MPH, offers practical strategies to clinicians seeking to stay up to date in the field of psychedelic medicine.
Rakesh Jain, MD, MPH, offers...
10/13/2022
Psychiatry & Behavioral Health
Andrew Penn, RN, MS, NP, CNS, APRN-BC
Podcasts
Recent Developments in Psychedelics With Andrew Penn
10/11/2022
Sana Symposium Steering Committee Member Andrew Penn, RN, MS, NP, CNS, APRN-BC, discusses developments in psychedelics, barriers to integration, reasons for usage hesitancy among patients and practitioners.
Sana Symposium Steering Committee Member Andrew Penn, RN, MS, NP, CNS, APRN-BC, discusses developments in psychedelics, barriers to integration, reasons for usage hesitancy among patients and practitioners.
Sana Symposium Steering...
10/11/2022
Psych Congress Network
News
Lynn-Marie Morski and Rosalind Watts, Most Influential Women in Psychedelics
02/22/2022
Heather Flint, Senior Digital Managing Editor
Sana Symposium Steering Committee Members, Lynn-Marie Morski, MD, JD, and Rosalind Watts, MD, named 2 of the 16 most influential women in the psychedelic space.
Sana Symposium Steering Committee Members, Lynn-Marie Morski, MD, JD, and Rosalind Watts, MD, named 2 of the 16 most influential women in the psychedelic space.
Sana Symposium Steering...
02/22/2022
Psych Congress Network
Charles Raison
Videos
The Impact of Psychedelics on the Brain
02/02/2022
Charles Raison, MD, discusses the history, pharmacology, and clinical potential of the lesser-known psychedelics, including Ibogain, 5-MeO-DMT, LSD, and DMT.
Charles Raison, MD, discusses the history, pharmacology, and clinical potential of the lesser-known psychedelics, including Ibogain, 5-MeO-DMT, LSD, and DMT.
Charles Raison, MD, discusses...
02/02/2022
Psych Congress Network
Raison and Penn
Videos
The History of Psychedelics
02/02/2022
Psych Congress Steering Committee Members, Charles Raison, MD, and Andrew Penn, MS, PMHNP, discuss a history of psychedelics, including indigenous origins of psychedelic use, key events in traditional and contemporary uses, and the historical...
Psych Congress Steering Committee Members, Charles Raison, MD, and Andrew Penn, MS, PMHNP, discuss a history of psychedelics, including indigenous origins of psychedelic use, key events in traditional and contemporary uses, and the historical...
Psych Congress Steering...
02/02/2022
Psych Congress Network
Penn_Jain
Bridging the Gap: Psychiatry, Psychotherapy, and Psychedelics
01/17/2022
Andrew Penn, MS, PMHNP, and Saundra Jain, MA, PsyD, LPC, discuss the key components of a therapeutic relationship and creating an optimal environment for healing in psychedelic-assisted therapy.
Andrew Penn, MS, PMHNP, and Saundra Jain, MA, PsyD, LPC, discuss the key components of a therapeutic relationship and creating an optimal environment for healing in psychedelic-assisted therapy.
Andrew Penn, MS, PMHNP, and...
01/17/2022
Psych Congress Network
Saundra Jain
Videos
Psychedelics Use Outside of the Clinical Setting
01/14/2022
Saundra Jain, MA, PsyD, LPC, discusses the use of psychedelic-assisted therapies outside of the clinical setting.
Saundra Jain, MA, PsyD, LPC, discusses the use of psychedelic-assisted therapies outside of the clinical setting.
Saundra Jain, MA, PsyD, LPC,...
01/14/2022
Psych Congress Network
Rakesh Jain
Podcasts
Ketamine Therapy for Bipolar Disorder
11/17/2021
Rakesh Jain, MD, MPH, discusses ketamine-assisted therapy for the treatment of bipolar disorder.
Rakesh Jain, MD, MPH, discusses ketamine-assisted therapy for the treatment of bipolar disorder.
Rakesh Jain, MD, MPH, discusses...
11/17/2021
Psych Congress Network
Rick Doblin
Podcasts
Do hallucinations automatically indicate a schizophrenia diagnosis?
09/30/2021
In his live Table Talk session at the Sana Symposium, Rick Doblin, PhD, Founder and Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS), answers the question of whether or not hallucinations automatically indicate...
In his live Table Talk session at the Sana Symposium, Rick Doblin, PhD, Founder and Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS), answers the question of whether or not hallucinations automatically indicate...
In his live Table Talk session...
09/30/2021
Psych Congress Network
Dr Rakesh Jain
Perspectives
Opportunities, Challenges, Integration, and Recommendations for Ketamine Treatment
09/30/2021
In Part 2 of this review, Rakesh Jain, MD, PhD, discusses opportunities, challenges, integration, and recommendations. Dr Jain spoke to participants in a live Table Talk session at the recent virtual Sana Symposium.
In Part 2 of this review, Rakesh Jain, MD, PhD, discusses opportunities, challenges, integration, and recommendations. Dr Jain spoke to participants in a live Table Talk session at the recent virtual Sana Symposium.
In Part 2 of this review, Rakesh...
09/30/2021
Psych Congress Network
News
Psychedelic-Assisted Therapies are Gaining Ground and Attention
09/29/2021
Heather Flint, Senior Digital Managing Editor
Psychedelic-assisted therapy is an emerging treatment that is gaining traction and attention.
Psychedelic-assisted therapy is an emerging treatment that is gaining traction and attention.
Psychedelic-assisted therapy is...
09/29/2021
Psych Congress Network
Rakesh Jain
Perspectives
Ketamine: Opportunities and Routes of Administration
09/28/2021
In this Table Talk review, Rakesh Jain, MD, PhD, Sana Symposium and Psych Congress steering committee member, provides an overview of his experience with using ketamine, including opportunities and routes of administration.
In this Table Talk review, Rakesh Jain, MD, PhD, Sana Symposium and Psych Congress steering committee member, provides an overview of his experience with using ketamine, including opportunities and routes of administration.
In this Table Talk review,...
09/28/2021
Psych Congress Network
News
Sana Symposium Recap: New Treatment Potential and Future Possibilities of Psychedelics
09/19/2021
Meagan Thistle
This weekend’s 3-day Inaugural Sana Symposium guided virtual attendees through the preparation, journey, and integration of psychedelic therapies.
This weekend’s 3-day Inaugural Sana Symposium guided virtual attendees through the preparation, journey, and integration of psychedelic therapies.
This weekend’s 3-day Inaugural...
09/19/2021
Psych Congress Network
News
5 Ways Clinicians Can Work With Patients Interested in Psychedelics
09/19/2021
Tom Valentino, Senior Editor
As public interest in psychedelics builds, practitioners must be ready to chart a path forward that balances helping patients while protecting both those patients and clinicians themselves, Saundra Jain, MA, PsyD, LPC, told Sana Symposium...
As public interest in psychedelics builds, practitioners must be ready to chart a path forward that balances helping patients while protecting both those patients and clinicians themselves, Saundra Jain, MA, PsyD, LPC, told Sana Symposium...
As public interest in...
09/19/2021
Psych Congress Network
News
The Future of MDMA as Possible Treatment for PTSD
09/19/2021
Erin McGuinness
Rick Doblin, PhD, Founder and Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS), Belmont, Massachusetts, discussed the possible future treatment landscape for psychedelics under legalization during a virtual...
Rick Doblin, PhD, Founder and Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS), Belmont, Massachusetts, discussed the possible future treatment landscape for psychedelics under legalization during a virtual...
Rick Doblin, PhD, Founder and...
09/19/2021
Psych Congress Network
News
Psilocybin Therapy as Depression Treatment: Lessons Learned
09/18/2021
Erin McGuinness
Rosalind Watts, PhD, Clinical Director, Synthesis Institute, London, England, discussed the therapeutic relationship in psilocybin treatment for depression during a virtual presentation at Sana Symposium.
Rosalind Watts, PhD, Clinical Director, Synthesis Institute, London, England, discussed the therapeutic relationship in psilocybin treatment for depression during a virtual presentation at Sana Symposium.
Rosalind Watts, PhD, Clinical...
09/18/2021
Psych Congress Network
News
Integration Framework for the Psychedelic Journey
09/18/2021
Heather Flint, Senior Digital Managing Editor
Julie Megler, PHH-NP, spoke about integration framework, including both “short-term integration” encompassing self-care as well as “long-term integration” comprising re-evaluation and reciprocity.
Julie Megler, PHH-NP, spoke about integration framework, including both “short-term integration” encompassing self-care as well as “long-term integration” comprising re-evaluation and reciprocity.
Julie Megler, PHH-NP, spoke...
09/18/2021
Psych Congress Network
News
Leading Their Patients on the Psychedelic Therapy Journey: Considerations for Clinicians
09/18/2021
Heather Flint, Senior Digital Managing Editor
There are several “important considerations for the clinician” in preparing to help lead their client on the journey of psychedelic therapies, said Julie Megler, PHH-NP, at today’s SANA Symposium.
There are several “important considerations for the clinician” in preparing to help lead their client on the journey of psychedelic therapies, said Julie Megler, PHH-NP, at today’s SANA Symposium.
There are several “important...
09/18/2021
Psych Congress Network
News
‘Container’ Creates an Ideal Home for Psychedelic Therapy
09/17/2021
Tom Valentino, Senior Editor
Andrew Penn, NP, and Saundra Jain, MA, PsyD, LPC, discussed the key components of a therapeutic relationship and creating an optimal environment for healing in psychedelic therapy during their Friday session at the Sana Symposium.
Andrew Penn, NP, and Saundra Jain, MA, PsyD, LPC, discussed the key components of a therapeutic relationship and creating an optimal environment for healing in psychedelic therapy during their Friday session at the Sana Symposium.
Andrew Penn, NP, and Saundra...
09/17/2021
Psych Congress Network
News
‘Bright’ Yet Cautionary Future for Psychedelics as Evidence-Based Medicine
09/17/2021
Meagan Thistle
The future of psychedelic medicine is rapidly emerging and clinicians should continue to follow this research before eventually accepting these drugs into their clinical practice, says Rakesh Jain, MD, MPH.
The future of psychedelic medicine is rapidly emerging and clinicians should continue to follow this research before eventually accepting these drugs into their clinical practice, says Rakesh Jain, MD, MPH.
The future of psychedelic...
09/17/2021
Psych Congress Network
News
“Egoic Style of Thinking” Allows Psychedelic Effects in the Human Brain
09/17/2021
Meagan Thistle
The “pivotal mental state,” made possible by the hyperplasticity of the brain, is where one pivots from “wellness” or “illness” when undergoing adaptive pressure or in a psychedelic state, Dr Carhart-Harris, told virtual attendees.
The “pivotal mental state,” made possible by the hyperplasticity of the brain, is where one pivots from “wellness” or “illness” when undergoing adaptive pressure or in a psychedelic state, Dr Carhart-Harris, told virtual attendees.
The “pivotal mental state,” made...
09/17/2021
Psych Congress Network
News
Association President: Psychedelics Emerging, but Obstacles to Mainstream Model Remain
09/14/2021
Tom Valentino, Senior Editor
Ahead of her sessions at the Sana Symposium, Lynn Marie Morski, MD, JD, president of the Psychedelic Medicine Association, discusses the path forward for psychedelic therapies fitting into the mainstream medical model and their potential...
Ahead of her sessions at the Sana Symposium, Lynn Marie Morski, MD, JD, president of the Psychedelic Medicine Association, discusses the path forward for psychedelic therapies fitting into the mainstream medical model and their potential...
Ahead of her sessions at the...
09/14/2021
Psych Congress Network
Andrew Penn_Charles Raison
Perspectives
What to Expect at the Sana Symposium
09/13/2021
Andrew Penn, RN, MS, NP, CNS, APRN-BC
Charles Raison, MD
Sana Symposium co-chairs, Andrew Penn, MS, PMHNP & Charles Raison, MD, give an update on what to expect at this weekend's virtual symposium.
Sana Symposium co-chairs, Andrew Penn, MS, PMHNP & Charles Raison, MD, give an update on what to expect at this weekend's virtual symposium.
Sana Symposium co-chairs, Andrew...
09/13/2021
Psych Congress Network
Andrea Turnipseed and Brent Turnipseed, MD, of Roots Behavioral Health
Videos
Identifying Patients Who Could Benefit From Ketamine-Assisted Therapy
08/30/2021
Andrea Turnipseed and Brent Turnipseed, MD, co-founders of Roots Behavioral Health, discuss the types of patients who do best with ketamine-assisted therapy, as well as what a clinician should look for in a potential referral source offering...
Andrea Turnipseed and Brent Turnipseed, MD, co-founders of Roots Behavioral Health, discuss the types of patients who do best with ketamine-assisted therapy, as well as what a clinician should look for in a potential referral source offering...
Andrea Turnipseed and Brent...
08/30/2021
Psych Congress Network
Michael Haichin, PharmD, BCMAS, Psychedelic Pharmacists Association
Videos
Pharmacists Play Vital Role in Psychedelic Medicine’s Emergence
08/23/2021
Michael Haichin, PharmD, BCMAS, co-founder of the Psychedelic Pharmacists Association, discusses the role of pharmacists in the emergence of psychedelic medicine.
Michael Haichin, PharmD, BCMAS, co-founder of the Psychedelic Pharmacists Association, discusses the role of pharmacists in the emergence of psychedelic medicine.
Michael Haichin, PharmD, BCMAS,...
08/23/2021
Psych Congress Network
Timothy Ko
Videos
DMT Offers Alternative for Treating Substance Use Disorders
08/12/2021
Timothy Ko, CEO of Entheon, explains why Entheon has chosen to focus on DMT as a treatment for substance use disorders.
Timothy Ko, CEO of Entheon, explains why Entheon has chosen to focus on DMT as a treatment for substance use disorders.
Timothy Ko, CEO of Entheon,...
08/12/2021
Psych Congress Network
Videos
The Role of Pharmacists in the Field of Psychedelics
06/07/2021
Cody Wenthur, PharmD, PhD, assistant professor of pharmacy at the University of Wisconsin-Madison, discusses the role of pharmacists in the field of psychedelics—from routine tasks to groundbreaking opportunities—and more.
Cody Wenthur, PharmD, PhD, assistant professor of pharmacy at the University of Wisconsin-Madison, discusses the role of pharmacists in the field of psychedelics—from routine tasks to groundbreaking opportunities—and more.
Cody Wenthur, PharmD, PhD,...
06/07/2021
Psych Congress Network
Videos
Saundra Jain, MA, PsyD, LPC, on What Clinicians Should Know About Psychedelic-Assisted Psychotherapy
05/24/2021
Saundra Jain, MA, PsyD, LPC, discusses key research findings around psychedelic-assisted psychotherapy, as well as what practicing clinicians should know about this emerging treatment option, including what providers should look for in...
Saundra Jain, MA, PsyD, LPC, discusses key research findings around psychedelic-assisted psychotherapy, as well as what practicing clinicians should know about this emerging treatment option, including what providers should look for in...
Saundra Jain, MA, PsyD, LPC,...
05/24/2021
Psych Congress Network
Andrew Penn, RN, MS, NP, CNS, APRN-BC, on Psychedelics That Mental Health Professionals Should Know
Videos
Andrew Penn, RN, MS, NP, CNS, APRN-BC, on Psychedelics That Mental Health Professionals Should Know
04/19/2021
Andrew Penn, RN, MS, NP, CNS, APRN-BC, founding member of the Organization of Psychedelic and Entheogenic Nurses (OPENurses) and a Sana Symposium steering committee member, discusses psychedelics that mental health professionals should be...
Andrew Penn, RN, MS, NP, CNS, APRN-BC, founding member of the Organization of Psychedelic and Entheogenic Nurses (OPENurses) and a Sana Symposium steering committee member, discusses psychedelics that mental health professionals should be...
Andrew Penn, RN, MS, NP, CNS,...
04/19/2021
Psych Congress Network
Lynn Marie Morski, MD, Esq, on Psychedelics Education for Providers
Videos
Lynn Marie Morski, MD, Esq, on Psychedelics Education for Providers
04/05/2021
Psychedelic Medicine Association president Lynn Marie Morski, MD, Esq., a Sana Symposium steering committee member, discusses the mission of the Psychedelic Medicine Association, bringing psychedelics education to front-line providers who are...
Psychedelic Medicine Association president Lynn Marie Morski, MD, Esq., a Sana Symposium steering committee member, discusses the mission of the Psychedelic Medicine Association, bringing psychedelics education to front-line providers who are...
Psychedelic Medicine Association...
04/05/2021
Psych Congress Network
Rakesh Jain, MD, MPH, on Emergence of Psychedelic Therapies: What Clinicians Need to Know
Videos
Rakesh Jain, MD, MPH, on Emergence of Psychedelic Therapies: What Clinicians Need to Know
03/22/2021
Sana Symposium steering committee member Rakesh Jain, MD, MPH, clinical professor in the Department of Psychiatry at the Texas Tech University Health Sciences Center School of Medicine and co-investigator for Psychedelics and Wellness...
Sana Symposium steering committee member Rakesh Jain, MD, MPH, clinical professor in the Department of Psychiatry at the Texas Tech University Health Sciences Center School of Medicine and co-investigator for Psychedelics and Wellness...
Sana Symposium steering...
03/22/2021
Psych Congress Network

Advertisement

About

The Sana Symposium serves as the premier forum to connect members from 3 key fields of practice—psychiatry, psychotherapy, and addiction treatment—for 3 days of cutting-edge, expertly crafted, clinically focused psychedelics education. This conference is produced in partnership with Psych Congress, Evolution of Psychotherapy, and the nation's leading Clinical Addiction Symposia.

Advertisement

December 9 ⁠–⁠ December 11
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
May 28 ⁠–⁠ May 31
See Full Calendar

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement